Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
63 participants
INTERVENTIONAL
2008-07-31
2010-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Consistent use of LIQUICURE as described will clear fungal nail infection. Clearing of nail fungal infection is defined by negative dermatophyte culture and visual improvement in nail characteristics within six months, with few, if any product-related adverse events.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Topical Application of Essential Oils to Treat Onchomycosis
NCT06417983
Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
NCT01302119
Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
NCT01270971
Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis
NCT00680134
Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis
NCT01431820
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LIQUICURE
Medical Device
LIQUICURE
Topical treatment, 1 time/day, 5 days/week
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LIQUICURE
Topical treatment, 1 time/day, 5 days/week
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects who have target toenail showing 20-65% involvement as judged by the clinical investigator
* 2 mm of clear nail proximally on great toenail / no lunula involvement
* Subject must be physically able to reach toes to clean them and apply product
* Subject is willing to discontinue use of other nail fungus treatment products and nail cosmetic products for duration of this study
* Subject is willing and available to return for study follow up
* Ability of the subject or legal representative to understand and provide signed consent for participating in the study
* Negative urine pregnancy test for women of child bearing age
* Females must be post menopausal or must agree to use approved contraceptives (actions, devices or medications to prevent or reduce the likelihood of pregnancy) throughout the study (Note: abstinence is NOT an accepted form of contraception)
Exclusion Criteria
* Negative KOH preparation or dermatophyte culture
* Thickness of nail greater than 3 mm
* Enrollment in another investigational drug or product protocol that would interfere with this study
* Continuation or use of other topical or pharmaceutical treatments for the condition; a wash-out period of at least four weeks after discontinuation of a topical product or 180 days after discontinuation of an oral product for treatment of nail fungus is required
* Chronic disease, including: diabetes, psoriasis, immune deficiency, severe foot injury, chronic vascular disease or any other condition that would decrease circulation to the extremities at the discretion of the investigator Pregnant or nursing females
* Investigators, Chesson personnel, or Chesson Scientific Advisory Board members or their immediate family
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chesson Laboratory Associates, Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Beth Goldstein, MD
Role: PRINCIPAL_INVESTIGATOR
Central Dermatology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Triangle Medical Research Associates
Cary, North Carolina, United States
Central Dermatology Center
Chapel Hill, North Carolina, United States
Wake Research Associates
Raleigh, North Carolina, United States
Crescent Medical Research
Salisbury, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Chesson Labs CT001-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.